Aug. 21 at 4:49 PM
$PFE continues leveraging its global pharmaceutical portfolio and research capabilities across multiple therapeutic areas. AERT reaffirmed FY2027 revenue guidance of
$80 million–
$84 million and adjusted EBITDA guidance of
$10 million–
$12 million.